AMP Increases its Hypothetical Position in ANTH Ahead of Phase 2 IgA Nephropathy Results


Today AMP increased its position in Anthera Pharmaceuticals by purchasing 8,389 shares at a share price of $1.49/share in a transaction totaling $12,500. Anthera is expected to report the results of its Phase 2 Blisibimod study in IgA nephropathy AMP by the end of Q3.

AMP has now allocated 2.91% of its hypothetical fund in Anthera with $37,500 invested.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon